Digital Therapeutics Find Opportunity in Healthcare Economics Outcomes

In the past decade, digital therapeutics (DTx) have emerged as effective management tools for various conditions, but healthcare professionals have been slow to prescribe them due to lack of knowledge, administrative challenges, and insurance issues. DTx companies face hurdles in clinical trials, FDA approval, and reimbursement, hindering their economic viability. To overcome these obstacles, companies are selling directly to employers to offer DTx services as part of employee benefits packages. Health Economics and Outcomes Research (HEOR) can help companies pivot to a direct-to-patient model, with a focus on proving the economic value of their products. Capturing health economics data and leveraging technology will be crucial for the success of DTx companies in the future.

Source link

error: Content is protected !!